How AstraZeneca’s $400bn tie-up with US rival Bristol Myers unravelled

The article details how a potential $400bn tie-up and merger between AstraZeneca and its US rival, Bristol Myers, ultimately unravelled. Had this mega-deal proceeded, it would have represented a notable return to major pharma megadeals.